Are Medtech Commercial Operations Ready For IDNs?
The recent expansion – and consolidation – of integrated delivery networks has been a game changer for the medtech industry. Purchasing power, formerly in the hands of physicians, is now held by non-clinical stakeholders at these large, data-driven networks.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.